French biotech Abivax announced positive Phase 3 results for obefazimod, an oral miRNA-124 enhancer for moderate-to-severe ulcerative colitis, showing a 16.4% placebo-adjusted clinical remission rate at 8 weeks across two studies. The compound demonstrated a favorable safety profile, with maintenance trials underway. The data surpassed earlier Phase 2 results and has significantly boosted market expectations, with peak sales projections raised to about $4 billion. Abivax is targeting regulatory submissions in the U.S. and Europe in 2026.